234 related articles for article (PubMed ID: 23020514)
1. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
2. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy.
Clingen PH; Wu JY; Miller J; Mistry N; Chin F; Wynne P; Prise KM; Hartley JA
Biochem Pharmacol; 2008 Jul; 76(1):19-27. PubMed ID: 18508035
[TBL] [Abstract][Full Text] [Related]
3. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
4. Increased γ-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin.
Adam-Zahir S; Plowman PN; Bourton EC; Sharif F; Parris CN
Chemotherapy; 2014; 60(5-6):310-20. PubMed ID: 26138778
[TBL] [Abstract][Full Text] [Related]
5. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy.
Wynne P; Newton C; Ledermann JA; Olaitan A; Mould TA; Hartley JA
Br J Cancer; 2007 Oct; 97(7):927-33. PubMed ID: 17848946
[TBL] [Abstract][Full Text] [Related]
6. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Ledermann JA; Gabra H; Jayson GC; Spanswick VJ; Rustin GJ; Jitlal M; James LE; Hartley JA
Clin Cancer Res; 2010 Oct; 16(19):4899-905. PubMed ID: 20719935
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity of primary human fibroblasts with defective unhooking of DNA interstrand cross-links.
Clingen PH; Arlett CF; Hartley JA; Parris CN
Exp Cell Res; 2007 Feb; 313(4):753-60. PubMed ID: 17188678
[TBL] [Abstract][Full Text] [Related]
9. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
10. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
[TBL] [Abstract][Full Text] [Related]
11. Analysis of DNA Interstrand Cross-Links and their Repair by Modified Comet Assay.
Swift LP; Castle L; McHugh PJ
Methods Mol Biol; 2020; 2119():79-88. PubMed ID: 31989516
[TBL] [Abstract][Full Text] [Related]
12. In vitro evidence for homologous recombinational repair in resistance to melphalan.
Wang ZM; Chen ZP; Xu ZY; Christodoulopoulos G; Bello V; Mohr G; Aloyz R; Panasci LC
J Natl Cancer Inst; 2001 Oct; 93(19):1473-8. PubMed ID: 11584063
[TBL] [Abstract][Full Text] [Related]
13. A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.
Alagpulinsa DA; Yaccoby S; Ayyadevara S; Shmookler Reis RJ
Cancer Biol Ther; 2015; 16(6):976-86. PubMed ID: 25996477
[TBL] [Abstract][Full Text] [Related]
14. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells.
Nojima K; Hochegger H; Saberi A; Fukushima T; Kikuchi K; Yoshimura M; Orelli BJ; Bishop DK; Hirano S; Ohzeki M; Ishiai M; Yamamoto K; Takata M; Arakawa H; Buerstedde JM; Yamazoe M; Kawamoto T; Araki K; Takahashi JA; Hashimoto N; Takeda S; Sonoda E
Cancer Res; 2005 Dec; 65(24):11704-11. PubMed ID: 16357182
[TBL] [Abstract][Full Text] [Related]
15. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
16. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
[TBL] [Abstract][Full Text] [Related]
17. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Cavallo F; Graziani G; Antinozzi C; Feldman DR; Houldsworth J; Bosl GJ; Chaganti RS; Moynahan ME; Jasin M; Barchi M
PLoS One; 2012; 7(12):e51563. PubMed ID: 23251575
[TBL] [Abstract][Full Text] [Related]
18. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.
Spanswick VJ; Craddock C; Sekhar M; Mahendra P; Shankaranarayana P; Hughes RG; Hochhauser D; Hartley JA
Blood; 2002 Jul; 100(1):224-9. PubMed ID: 12070031
[TBL] [Abstract][Full Text] [Related]
19. Advances in understanding the complex mechanisms of DNA interstrand cross-link repair.
Clauson C; Schärer OD; Niedernhofer L
Cold Spring Harb Perspect Biol; 2013 Oct; 5(10):a012732. PubMed ID: 24086043
[TBL] [Abstract][Full Text] [Related]
20. Distortion-dependent unhooking of interstrand cross-links in mammalian cell extracts.
Smeaton MB; Hlavin EM; McGregor Mason T; Noronha AM; Wilds CJ; Miller PS
Biochemistry; 2008 Sep; 47(37):9920-30. PubMed ID: 18702509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
